Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT05192616
Other study ID # iliCo Study
Secondary ID
Status Not yet recruiting
Phase
First received
Last updated
Start date February 15, 2022
Est. completion date May 30, 2025

Study information

Verified date December 2021
Source iVascular S.L.U.
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The objective of this prospective, multicenter, non-randomized, single-arm observational study is to evaluate the efficacy and the safety of the iCover covered stent for the treatment of de novo aorto-iliac atherosclerotic lesions in patients with symptomatic arteriopathy of the lower limbs (Rutherford class 2 to 5).


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 214
Est. completion date May 30, 2025
Est. primary completion date May 30, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion criteria 1. = 18 years of age 2. Rutherford clinical stage 2 to 5 3. Atheromatous aorto-iliac lesions evidenced by duplex scan, CT angiography or arteriography. 4. De novo atheromatous lesion of the aortoiliac segment 5. Patient informed about the study and collection of the patient's informed consent agreement. Exclusion criteria Subjects will not be eligible to participate in the study if any of the following conditions are present in the subject: 1. Protected adult patients, guardianship, curatorship, safeguard of justice 2. Woman with possibility of pregnancy 3. Patient with asymptomatic atheromatous lesions 4. Patient with inflow lesion in the infrarenal aorta 5. Patient treated with Covered endovascular reconstruction of aortic bifurcation (CERAB reconstruction) 6. Acute ischemia or acute thrombosis 7. Non-atherosclerotic disease 8. History of coagulopathy 9. Severe comorbidities with life expectancy <2 years 10. Contraindication to taking antiplatelet aggregation therapy (aspirin or clopidogrel). The patient must be able to take an antiplatelet aggregation for at least 3 months after the procedure 11. Patient participating in another clinical study which may interfere with the results 12. Comorbidity or any reason which, according to the investigator, could limit the participation, the patient's adherence with the follow-up or the scientific integrity of the study 13. Lesion near or adjacent to an aneurysm 14. Inability to follow-up during the trial 15. Patient objection to participate in the trial

Study Design


Intervention

Device:
Covered stent implantation
Percutaneous transluminal angioplasty (PTA) with iCover covered stent for the treatment of de novo aorto-iliac occlusive lesions

Locations

Country Name City State
Belgium Onze Lieve Vrouw Aalst Aalst
Belgium Imelda Bonheiden Bonheiden
Belgium Az Sint Blasius Dendermonde Dendermonde
Belgium ZOL Genk Genk
France Centre Hospitalier Universitaire de Brest Brest
France CHU Pitié Salpêtrière Paris
France Hôpital Paris Saint Joseph Paris
France Hôpital privé Saint-Martin Pessac
France Clinique Rhena Strasbourg
France Hôpital privé Villeneuve d'Ascq Villeneuve-d'Ascq
Germany Herzzentrum Bad Krozingen Bad Krozingen Baden-Württemberg
Germany KEH Berlin Berlin
Germany MVZ Kaiserslautern Kaiserslautern Rhineland-Palatinate
Germany Universitätsklinikum Leipzig Leipzig Saxony
Germany Imland Klinik Rendsburg Rendsburg
Spain Hospital de Santa Creu i Sant Pau Barcelona
Spain Hospital Universitari Germans Trias i Pujol Barcelona
Spain Hospital de Cruces Bilbao

Sponsors (1)

Lead Sponsor Collaborator
iVascular S.L.U.

Countries where clinical trial is conducted

Belgium,  France,  Germany,  Spain, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of Participants With Target Lesion Primary Patency Primary patency defined as the lack of restenosis and no need for reintervention of the target lesion at 12-month follow-up. 12 Months
Secondary Medical safety of the iCover covered stent up to 1 month Medical safety of the iCover covered stent will be evaluated by the occurrence of complications from day 0 to month 1:
General complications: All cause death, Major adverse events (stroke, myocardial infarction, procedural-related serious adverse events and device failure or malfunction)
Major local complications in the treated lesion or punctured site:
Iliac arterial rupture
Retroperitoneal hematoma
Thrombosis of the iliac axis on the homolateral side
Need for surgery to achieve hemostasis
Bleeding with loss of more than 2 g / dl of hemoglobin
False aneurysm at the puncture site
Hematoma at the puncture site requiring manual compression at 24 hours, or preventing resumption of walking at 24 hours
Appearance of ischemia on the ipsilateral side
From day 0 up to 1 month
Secondary Number of participants with major amputation at target limb Amputations above the ankle of the target leg will be counted. 1, 6, 12, 24 months after index procedure
Secondary Primary sustained clinical improvement Primary sustained clinical improvement defined as a sustained upward shift of 1 category of the Rutherford classification for patients with claudication, and by wound healing and rest pain resolution for patients in critical limb ischemia, without the need for repeated target lesion revascularization in surviving patients 1, 6, 12, 24 months after index procedure
Secondary Number of Participants With Target Lesion Primary Patency Primary patency rate defined as the lack of restenosis and no need for reintervention of the target lesion. 6, 24 months after index procedure
Secondary Target lesion revascularization (TLR) Target lesion revascularization (TLR) defined as the need for repeated procedures (endovascular or surgical) due to a problem arising from the lesion initially treated in surviving patients with preserved limbs 1, 6, 12, 24 months after index procedure
Secondary Target vessel revascularization (TVR) Target vessel revascularization (TVR) defined as the need for repeated procedures (endovascular or surgical) due to a problem arising remote from the vessel initially treated in surviving patients with preserved limbs 1, 6, 12, 24 months after index procedure
Secondary Change in Walking Impairment Questionnaire from baseline The Walking Impairment Questionnaire values will be recorded and compared to the baseline values. This questionnaire is a validated tool to assess walking capability in patients with Peripheral Arterial Disease in different situations. 1, 6, 12, 24 months after index procedure
Secondary Change in quality of life from baseline, as measured by EQ-5D The EQ-5D Questionnaire values will be recorded and compared to the baseline values. It is a validated questionnaire to measure the quality of life based on 5 different parameters. Worst possible score in this study would be 0, best possible score would be 1. In addition, the patient indicates her/his current health on an analog scale from 0 (worst) to 100 (best). 1, 6, 12, 24 months after index procedure
See also
  Status Clinical Trial Phase
Recruiting NCT06032065 - SMART Exercise for PAD Phase 3
Active, not recruiting NCT03987061 - MOTIV Bioresorbable Scaffold in BTK Artery Disease N/A
Recruiting NCT03506633 - Impacts of Mitochondrial-targeted Antioxidant on Peripheral Artery Disease Patients N/A
Active, not recruiting NCT03506646 - Dietary Nitrate Supplementation and Thermoregulation N/A
Active, not recruiting NCT04677725 - NEtwork to Control ATherothrombosis (NEAT Registry)
Recruiting NCT06047002 - Personalised Antiplatelet Therapy for Patients With Symptomatic Peripheral Arterial Disease
Completed NCT03185052 - Feasibility of Outpatient Care After Manual Compression in Patients Treated for Peripheral Arterial Disease by Endovascular Technique With 5F Sheath Femoral Approach N/A
Recruiting NCT05992896 - A Study of Loco-Regional Liposomal Bupivacaine Injection Phase 4
Completed NCT04635501 - AbsorbaSeal (ABS 5.6.7) Vascular Closure Device Trial N/A
Recruiting NCT04584632 - The Efemoral Vascular Scaffold System (EVSS) for the Treatment of Patients With Symptomatic Peripheral Vascular Disease From Stenosis or Occlusion of the Femoropopliteal Artery N/A
Withdrawn NCT03994185 - The Merit WRAPSODY™ Endovascular Stent Graft for Treatment of Iliac Artery Occlusive Disease N/A
Withdrawn NCT03538392 - Serranator® Alto Post Market Clinical Follow Up (PMCF) Study
Recruiting NCT02915796 - Autologous CD133(+) Cells as an Adjuvant to Below the Knee Percutaneous Transluminal Angioplasty Phase 1
Active, not recruiting NCT02900924 - Observational Study to Evaluate the BioMimics 3D Stent System: MIMICS-3D
Completed NCT02901847 - To Evaluate the Introduction of a Public Health Approach to Peripheral Arterial Disease (PAD) Using National Centre for Sport and Exercise Medicine Facilities. N/A
Withdrawn NCT02126540 - Trial of Pantheris System, an Atherectomy Device That Provides Imaging While Removing Plaque in Lower Extremity Arteries N/A
Not yet recruiting NCT02387450 - Reduced Cardiovascular Morbi-mortality by Sildenafil in Patients With Arterial Claudication Phase 2/Phase 3
Not yet recruiting NCT02455726 - Magnesium Oral Supplementation to Reduce Pain Inpatients With Severe Peripheral Arterial Occlusive Disease N/A
Completed NCT02022423 - Physical Activity Daily - An Internet-Based Walking Program for Patients With Peripheral Arterial Disease N/A
Completed NCT02384980 - Saving Life and Limb: FES for the Elderly With PAD Phase 1